Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Orum Therapeutics
Biotech
BMS dumps $100M degrader-antibody conjugate over ph. 1 data
BMS has axed the degrader-antibody conjugate it bought from Orum Therapeutics for $100 million, walking away from the asset after seeing phase 1 data.
Nick Paul Taylor
Sep 18, 2026 3:41am
Former Roche oncology head turns to Tubulis—Chutes & Ladders
Jan 9, 2026 8:30am
Vertex mines for more gene editing riches with $15M Orum deal
Jul 16, 2024 7:00am
BMS snags another ADC with modest $100M Orum deal
Nov 6, 2023 7:00am
Orum adds $54M to 2019 series B to move ADCs into the clinic
Jun 23, 2021 9:41am
Orum bags $30M to build out its platform to drug the 'undruggable'
Jul 17, 2019 12:00am
